Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Equity Capital Markets

Established in 2012, <a href="https://www.smartkarma.com/entities/26754" target="_blank" data-smartkarma-citation="entities:26754:1">Carelabs Co Ltd (263700 KS)</a> operates leading healthcare, beauty care, and cosmetics surgery O2O (online-to-offline) platforms (goodoc and babitalk). In addition, Carelabs provides digital marketing services and CRM software for the healthcare industry. <a href="https://www.smartkarma.com/entities/26754" target="_blank" data-smartkarma-citation="entities:26754:1">Carelabs Co Ltd (263700 KS)</a> is getting ready for an IPO in March. The IPO price range is 15,000 won to 18,000 won and the initial market cap is expected to be between 97 billion won and 116 billion won. The company is expected…

Established in 2012, Carelabs Co Ltd (263700 KS) operates leading healthcare, beauty care, and cosmetics surgery O2O (online-to-offline) platforms (goodoc and babitalk). In addition, Carelabs provides digital marketing services and CRM software for the healthcare industry. Carelabs Co Ltd (263700 KS) is getting ready for an IPO in March. The IPO price range is 15,000 won to 18,000 won and the initial market cap is expected to be between 97 billion won and 116 billion won. The company is expected…

Carelabs IPO Preview (Part 1) - Leading Provider of Healthcare and Cosmetics Surgery O2O Platforms

Korea / Special Sits, Pairs, Index Rebalancing, Clepsydra Capital

Sanghyun Park

Korea / Special Sits, Pairs, Index Rebalancing

Thematic (Sector/Industry)

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a biosimilar maker either. It makes new biomedical products. A majority of Korea's pharmaceutical makers are still generic drug makers. The likes of Celltrion and Samsung Bioepis have emerged as a biosimilar maker. But they are still a few. Biomedical makers are even rarer. Hanmi Pharmaceutical is one of these rare breeds. Now, another biomedical maker…

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

South Korea

INFINITT Healthcare Co., Ltd. develops and markets PACS(Picture Archiving and Communication System). Picture Archiving and Communication System is medical imaging and information solution.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Infinitt Healthcare (071200 KS)

Carelabs IPO Preview (Part 1) - Leading Provider of Healthcare and Cosmetics Surgery O2O Platforms

Established in 2012, Carelabs Co Ltd (263700 KS) operates leading healthcare, beauty care, and cosmetics surgery O2O (online-to-offline) platforms...

Douglas Kim

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Sanghyun Park

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)